m+Medelevator.RU
← Поиск публикаций
Scientific reports · 2026

Computational strategies for unraveling insights from known inhibitors for further lead optimization: A case study on Celecoxib analogues.

СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Grewal Sonam, Ghosh Biswayan, Narayan Ujjwal, Aparoy Polamarasetty

Аннотация

Inhibition of Cyclooxygenase-2 (COX-2) represents a well-established and promising strategy in the development of anti-inflammatory drugs, given its pivotal role in mediating inflammation. Selective inhibition of COX-2 over COX-1 is critical for reducing the gastrointestinal side effects commonly associated with traditional nonsteroidal anti-inflammatory drugs (NSAIDs). Celecoxib is a widely recognized selective COX-2 inhibitor that has been extensively studied for its therapeutic efficacy. Its structural analogues differ in their biological activities despite their close structural resemblance. The objective of the present work is to systematically investigate the influence of subtle structural modifications on celecoxib, focusing on its COX-2 inhibitory activity profile. A dataset comprising 375 analogues was curated based on the structural similarity with celecoxib. Molecular descriptors were calculated using RDKit and Mordred, followed by correlation analysis. Weak correlation was observed between the computed molecular descriptors and biological activity. Molecular docking studies were performed using Genetic Optimisation for Ligand Docking (GOLD). Critical interactions were identified by interaction analysis. Further, the Structure-Activity Landscape Index (SALI) analysis aided in identifying the activity cliffs in the dataset. The findings from the interaction analysis and SALI offer a comprehensive understanding of the Structure-Activity relationship of celecoxib analogues and deliver valuable insights for further lead optimization.

Предметные рубрики MeSH

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты